NCT05846607 is a NA clinical trial of Intervention oral supplement in Gastic Antrum, sponsored by Huashan Hospital.

Who is sponsoring NCT05846607?

NCT05846607 is sponsored by Huashan Hospital.

What drugs are being tested in NCT05846607?

Interventions in NCT05846607: Intervention oral supplement.

What condition does NCT05846607 study?

NCT05846607 studies Gastic Antrum.

Is NCT05846607 still recruiting?

NCT05846607 is currently status unknown. Last updated 6 May 2023.

Last reviewed 2023-05-06 · How we verify

NCT05846607

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Deep Learning Approach to Identify Patients With Full Stomach on Ultrasonography

Status unknown NA Last updated 6 May 2023

What this trial tests

NA trial testing Intervention oral supplement in Gastic Antrum in 800 participants. Status unknown.

Timeline

26 April 2023

Primary endpoint
15 September 2023

15 September 2023

Quick facts

Lead sponsor	Huashan Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	800
Start date	26 April 2023
Primary completion	15 September 2023
Estimated completion	15 September 2023
Sites	1 location across China

Drugs / interventions tested

Intervention oral supplement

Conditions studied

Gastic Antrum — all drugs for Gastic Antrum →

Sponsor

Huashan Hospital

Who can join

Adults 18 to 80, any sex, with Gastic Antrum. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Preoperative gastric ultrasonography is a newly developed tool used to evaluate gastric content and volume in assessing perioperative aspiration risk and guide anaesthetic management. And then build up effective clinical predictive models for identification of full stomach, which can predict the high aspiration risk.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Huashan Hospital trials

Trials by the same sponsor.

NCT07469735 — Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma · NA · not yet recruiting
NCT07364487 — This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis · EARLY_PHASE1 · withdrawn
NCT07369830 — The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function · NA · recruiting
NCT07185373 — Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · Phase 2, PHASE3 · not yet recruiting
NCT07075029 — RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05846607 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huashan Hospital
Last refreshed: 6 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05846607.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing